Deferred treatment as part of AS ➔ WW model (n = 23,649) | Deferred treatment WW (n = 7286) | Radical prostatectomy RP (n = 32,537) | Radio therapy RT (n = 19,019) | Anti-androgen monotherapy AA (n = 7178) | Gonadotropin releasing hormone agonists GnRH (n = 29,074) | Total (n = 118,743) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age, median (Q1-Q3) | 69 | (64–74) | 77 | (73–81) | 63 | (59–67) | 67 | (62–71) | 76 | (71–81) | 77 | (71–82) | 69 | (63–76) |
Age, n (%) | ||||||||||||||
≤ 55 | 1008 | (4.3) | 33 | (0.5) | 4120 | (12.7) | 875 | (4.6) | 55 | (0.8) | 341 | (1.2) | 6432 | (5.4) |
56–60 | 2332 | (9.9) | 116 | (1.6) | 6942 | (21.3) | 2403 | (12.6) | 153 | (2.1) | 803 | (2.8) | 12,749 | (10.7) |
61–65 | 4543 | (19.2) | 296 | (4.1) | 10,356 | (31.8) | 4775 | (25.1) | 475 | (6.6) | 1959 | (6.7) | 22,404 | (18.9) |
66–70 | 6172 | (26.1) | 800 | (11.0) | 8635 | (26.5) | 6053 | (31.8) | 964 | (13.4) | 3535 | (12.2) | 26,159 | (22.0) |
71–80 | 8241 | (34.8) | 3929 | (53.9) | 2461 | (7.6) | 4880 | (25.7) | 3734 | (52.0) | 13,167 | (45.3) | 36,412 | (30.7) |
81+ | 1353 | (5.7) | 2112 | (29.0) | 23 | (0.1) | 33 | (0.2) | 1797 | (25.0) | 9266 | (31.9) | 14,584 | (12.3) |
Year of diagnosis, n (%) | ||||||||||||||
1992–1997 | 558 | (2.4) | 243 | (3.3) | 513 | (1.6) | 245 | (1.3) | 22 | (0.3) | 561 | (1.9) | 2142 | (1.8) |
1998–2004 | 4472 | (18.9) | 2144 | (29.4) | 7113 | (21.9) | 5373 | (28.3) | 1024 | (14.3) | 8672 | (29.8) | 28,798 | (24.3) |
2005–2008 | 5770 | (24.4) | 2369 | (32.5) | 9363 | (28.8) | 4894 | (25.7) | 1742 | (24.3) | 9353 | (32.2) | 33,491 | (28.2) |
2009–2011 | 5969 | (25.2) | 1679 | (23.0) | 7911 | (24.3) | 4804 | (25.3) | 1841 | (25.6) | 5893 | (20.3) | 28,097 | (23.7) |
2012–2014 | 6880 | (29.1) | 851 | (11.7) | 7637 | (23.5) | 3703 | (19.5) | 2549 | (35.5) | 4595 | (15.8) | 26,215 | (22.1) |
T stage, n (%) | ||||||||||||||
T1a | 2564 | (10.8) | 440 | (6.0) | 276 | (0.8) | 99 | (0.5) | 25 | (0.3) | 129 | (0.4) | 3533 | (3.0) |
T1b | 963 | (4.1) | 499 | (6.8) | 247 | (0.8) | 194 | (1.0) | 101 | (1.4) | 365 | (1.3) | 2369 | (2.0) |
T1c | 15,243 | (64.5) | 2373 | (32.6) | 20,010 | (61.5) | 7496 | (39.4) | 1580 | (22.0) | 3559 | (12.2) | 50,261 | (42.3) |
T2 | 4738 | (20.0) | 2464 | (33.8) | 10,881 | (33.4) | 7201 | (37.9) | 2659 | (37.0) | 8927 | (30.7) | 36,870 | (31.1) |
T3 | 0 | (0.0) | 1362 | (18.7) | 979 | (3.0) | 3883 | (20.4) | 2436 | (33.9) | 12,517 | (43.1) | 21,177 | (17.8) |
T4 | 0 | (0.0) | 49 | (0.7) | 12 | (0.0) | 71 | (0.4) | 280 | (3.9) | 3002 | (10.3) | 3414 | (2.9) |
TX/Missing | 141 | (0.6) | 99 | (1.4) | 132 | (0.4) | 75 | (0.4) | 97 | (1.4) | 575 | (2.0) | 1119 | (0.9) |
N stage, n (%) | ||||||||||||||
N0 | 1831 | (7.7) | 292 | (4.0) | 7472 | (23.0) | 6004 | (31.6) | 766 | (10.7) | 1418 | (4.9) | 17,783 | (15.0) |
N1 | 0 | (0.0) | 44 | (0.6) | 278 | (0.9) | 317 | (1.7) | 321 | (4.5) | 1627 | (5.6) | 2587 | (2.2) |
NX | 21,818 | (92.3) | 6950 | (95.4) | 24,787 | (76.2) | 12,698 | (66.8) | 6091 | (84.9) | 26,029 | (89.5) | 98,373 | (82.8) |
Gleason Grade Group /WHO, n (%) | ||||||||||||||
GGG1 | 20,019 | (84.7) | 2860 | (39.3) | 16,783 | (51.6) | 6653 | (35.0) | 1181 | (16.5) | 3226 | (11.1) | 50,722 | (42.7) |
GGG2 | 2295 | (9.7) | 1469 | (20.2) | 8564 | (26.3) | 4750 | (25.0) | 1537 | (21.4) | 3398 | (11.7) | 22,013 | (18.5) |
GGG3 | 969 | (13.3) | 3291 | (10.1) | 3007 | (15.8) | 1476 | (20.6) | 4209 | (14.5) | 12,952 | (10.9) | ||
GGG2–3 | 202 | (0.9) | 257 | (3.5) | 790 | (2.4) | 388 | (2.0) | 168 | (2.3) | 1331 | (4.6) | 3136 | (2.6) |
GGG4 | 662 | (9.1) | 1792 | (5.5) | 2025 | (10.6) | 1321 | (18.4) | 6155 | (21.2) | 11,955 | (10.1) | ||
GGG5 | 202 | (2.8) | 687 | (2.1) | 1496 | (7.9) | 1028 | (14.3) | 6874 | (23.6) | 10,287 | (8.7) | ||
Only WHO-grade | 1096 | (4.6) | 740 | (10.2) | 600 | (1.8) | 671 | (3.5) | 315 | (4.4) | 3055 | (10.5) | 6477 | (5.5) |
Missing | 37 | (0.2) | 127 | (1.7) | 30 | (0.1) | 29 | (0.2) | 152 | (2.1) | 826 | (2.8) | 1201 | (1.0) |
PSA, median (Q1-Q3) | 6.0 | (4.2–8.2) | 18 | (12–26) | 6.8 | (4.8–10) | 10 | (6.4–18) | 22 | (12–47) | 45 | (19–139) | 9.9 | (5.8–24) |
Mode of detection, n (%) | ||||||||||||||
Screeningf | 10,024 | (42.4) | 1842 | (25.3) | 17,060 | (52.4) | 8119 | (42.7) | 2020 | (28.1) | 3912 | (13.5) | 42,977 | (36.2) |
LUTS | 7705 | (32.6) | 2572 | (35.3) | 7453 | (22.9) | 5133 | (27.0) | 3134 | (43.7) | 12,024 | (41.4) | 38,021 | (32.0) |
Other symptoms | 4258 | (18.0) | 2127 | (29.2) | 5606 | (17.2) | 4244 | (22.3) | 1743 | (24.3) | 10,962 | (37.7) | 28,940 | (24.4) |
Missing | 1662 | (7.0) | 745 | (10.2) | 2418 | (7.4) | 1523 | (8.0) | 281 | (3.9) | 2176 | (7.5) | 8805 | (7.4) |
CCI, n (%) | ||||||||||||||
0 | 15,370 | (65.0) | 4257 | (58.4) | 25,259 | (77.6) | 13,369 | (70.3) | 4275 | (59.6) | 16,427 | (56.5) | 78,957 | (66.5) |
1 | 4228 | (17.9) | 1435 | (19.7) | 3955 | (12.2) | 3172 | (16.7) | 1461 | (20.4) | 6179 | (21.3) | 20,430 | (17.2) |
2 | 2356 | (10.0) | 945 | (13.0) | 1971 | (6.1) | 1511 | (7.9) | 806 | (11.2) | 3737 | (12.9) | 11,326 | (9.5) |
3+ | 1695 | (7.2) | 649 | (8.9) | 1352 | (4.2) | 967 | (5.1) | 636 | (8.9) | 2731 | (9.4) | 8030 | (6.8) |
Risk category, n (%) | ||||||||||||||
1 | 7546a | (31.9) | 1001b | ‘(13.7) | 8985c | (27.6) | 3735d | (19.6) | 922e | (12.8) | 6854e | (23.6) | ||
2 | 13,515a | (57.1) | 1004b | ‘(13.8) | 9997c | (30.7) | 1563d | (8.2) | 870e | (12.1) | 2585e | (8.9) | ||
3 | 2588a | (10.9) | 947b | ‘(13.0) | 5094c | (15.7) | 2285d | (12.0) | 1495e | (20.8) | 2855e | (9.8) | ||
4 | 1307b | ‘(17.9) | 5893c | (18.1) | 2805d | (14.7) | 1162e | (16.2) | 1811e | (6.2) | ||||
5 | 1281b | ‘(17.6) | 2480c | (7.6) | 1844d | (9.7) | 1007e | (14.0) | 3605e | (12.4) | ||||
6 | 1746b | ‘(24.0) | 88c | (0.3) | 2146d | (11.3) | 634e | (8.8) | 2468e | (8.5) | ||||
7 | 2658d | (14.0) | 492e | (6.9) | 1231e | (4.2) | ||||||||
8 | 1983d | (10.4) | 596e | (8.3) | 7665e | (26.4) |